## **DOES FASTING DURING RAMADAN AFFECT RENAL FUNCTIONS OF** PATIENTS WITH CHRONIC KIDNEY DISEASE?

Ekrem KARA<sup>1</sup>, Osman Z. Sahin<sup>1</sup>, Bayram Kizilkaya<sup>1</sup>, Burcu Ozturk<sup>1</sup>, Gokhan Pusuroglu<sup>1</sup>, Safak Yildirim<sup>1</sup>, Tuncay Sahutoglu<sup>2</sup>

<sup>1</sup>Recep Tayyip Erdogan University, Faculty of Medicine, Department of Internal Medicine, Division of Nephrology, Rize, Turkey. <sup>2</sup> Sisli Etfal Training and Research Hospital, Department of Nephrology, Istanbul, Turkey.

## Objectives:

Fasting during Ramadan represents one of the five pillars of the Islamic creed. Although not mandatory for patients, a lot of Muslims fast in Ramadan, which may cause decline in renal functions in patients with chronic kidney disease (CKD). However, there are no guidelines or standardized protocols about the patients with CKD fasting in Ramadan. In this study, we aimed to assess the impact of fasting during Ramadan on renal functions in patients with CKD.

A total of 94 stage 3 to 5 CKD patients (male/female: 56/38, age: 65.4±11.6 years) with stable kidney function were recruited to this prospective observational study. All patients were instructed regarding possible deleterious effects of dehydration, and patients themselves chose whether to fast or not. Patients were divided into 2 groups according to their fasting status during Ramadan; fasting group (n: 45, male/female: 31/14, age: 66.8±10.3 years) and nonfasting group (n: 49, male/female: 25/24, age: 64.1±12.6 years). Clinical and laboratory data including serum urea, creatinine, estimated glomerular filtration rate (e-GFR), spot urine protein/creatinine ratio (PCR) was recorded before and after Ramadan.

<b>[able 1.</b> Baseline characteristics of study participants.				Table 2. Changes in clinical and laboratory parameters after Ramadan according to fasting status.							Table 3. Differences in rena	al functions a	fter Ramadan acco	ording to fasting status.	
	Fasting (n: 45)	Non-fasting (n: 49)	P-value		Fastin	ng (n: 45)		Non-fast	ing (n: 49)				Fasting (n: 45)	Non-fasting (n: 49)	P val
Age (years)	66.8±10.3	64.1±12.6	0.258	Parameters	Before	After	Р	Before	After	Р					
Gender (male, %)	31 (%68.8)	25 (%51)	0.078		Ramadan	Ramadan	value	Ramadan	Ramadan	value	$\geq$ 30% rise of serum creat	tinine (n, %)	4 (8.8%)	4 (8.1%)	0.90
Weight (kg)	78.5±15.6	79.2±16.2	0.623	Weight (kg)	78.5±15.6	78.8±16.1	0.368	79.2±16.2	79.6±17.1	0.390	Change in e-GI	FR (mL/min)	+1.82±15.81	-2.03±8.23	0.31
BMI (kg/m2)	24.2±0.6	24.6±0.4	0.536	$BMI (kg/m^2)$	24.2±0.6	24.3±0.5	0.472	24.6±0.4	24.8±0.5	0.475	> 25% drop of e	GFR (n %)	7 (15.5%)	6 (12.2%)	0.64
Divii (kg/m/)	21.2-0.0	10000		Systolic BP (mmHg)	147.5±27.5	146.8±28.1	0.523	156.7±32.4	159.5±32.1	0.586	22070 arop 0j e-01 R (n, 70)		1 (15.576)	0 (12.270)	0.0-
Systolic BP (mm Hg)	147.5±27.5	156.7±32.4	0.239	Diastolic BP (mmHg)	87.0±14.5	86.4±14.4	0.684	90.7±17.6	90.2±17.4	0.691	Change in protein	nuria (mg/g)	-0.257±1.480	+0.201±1.373	0.16
Diastolic BP (mm Hg)	87.0±14.5	90.7±17.6	0.427	FPG (mg/dl)	116.9±39.1	120.3±32.2	0.515	124.7±50.2	136.5±69.9	0.147	a CEP. Estimated alementar filt	wation wata			
DM (n, %)	11 (24.4%)	19 (38.7%)	0.136	Urea (mg/dl)	66.5±25.4	68.8±25.1	0.630	90.0±41.4	84.4±35.7	0.163	e-GFK. Estimatea giomeratar jui	ration rate			
tihypertensive medication (n, %)				Creatinine (mg/dl)	1.64±0.41	1.64±0.48	0.962	2.22±0.99	2.33±1.11	0.125					
Diverties	15 (33 3%)	23 (46 9%)	0 179	e-GFR (mL/min)	42.6±9.8	44.4±15.5	0.444	31.9±12.4	29.8±13.7	0.090	Table 4. Multiple linear regr	ression analy	sis of the factors th	at may predicts ≥25% o	drop in
Dunenes	10 (00.070)		0.175	Uric acid (mmol/L)	7.9±2.0	7.8±1.8	0.960	7.8±2.5	7.6±1.5	0.087	in fasting group after Rama	dan.			
CCB	20 (44.4%)	30 (61.2%)	0.103	Sodium (mmol/l)	140.0±2.8	139.9±2.8	0.966	140.4±2.4	140.4±2.6	0.976					
RAS blockers	19 (42.2%)	22 (44.8%)	0.794	Potassium (meq/L)	4.7±0.6	5.4±0.7	0.397	4.7±0.5	4.9±0.5	0.094	1,	Beta	95% Confidence	Interval P	value
							0.015								
Beta blockers	14 (31.1%)	19 (38.7%)	0.484	Hemoglobin (g/dl)	13.3±1.5	12.9±1.6	0.015	12.1±1.9	12.0±1.0	0.481			T	T	
Beta blockers Alpha blockers	14 (31.1%) 10 (22.2%)	19 (38.7%) 10 (20.4%)	0.484 0.830	Hemoglobin (g/dl) Albumin (g/L)	13.3±1.5 4.2±0.5	12.9±1.6 4.1±0.3	0.013	12.1±1.9 4.0±0.2	12.0±1.0 4.0±0.4	0.481 0.082			Lower	Upper	
Beta blockers Alpha blockers Baseline creatinine (mg/dL)	14 (31.1%) 10 (22.2%) 1.64±0.41	19 (38.7%) 10 (20.4%) 2.22±0.99	0.484 0.830 < 0.001	Hemoglobin (g/dl) Albumin (g/L) Calcium (mg/dl)	13.3±1.5 4.2±0.5 9.4±0.6	12.9±1.6 4.1±0.3 9.2±0.4	0.013 0.074 0.012	12.1±1.9 4.0±0.2 9.2±0.6	12.0±1.0 4.0±0.4 9.3±0.5	0.481 0.082 0.307	Advanced age	0.403	Lower 0.003	Upper 0.020 0.	.010
Beta blockers Alpha blockers Baseline creatinine (mg/dL)	14 (31.1%) 10 (22.2%) 1.64±0.41	19 (38.7%) 10 (20.4%) 2.22±0.99	0.484 0.830 < <i>0.001</i>	Hemoglobin (g/dl) Albumin (g/L) Calcium (mg/dl) Phosphorus (mg/dl)	13.3±1.5 4.2±0.5 9.4±0.6 3.6±0.6	12.9±1.6 4.1±0.3 9.2±0.4 3.7±0.7	0.013 0.074 0.012 0.316	12.1±1.9 4.0±0.2 9.2±0.6 3.7±0.7	12.0±1.0 4.0±0.4 9.3±0.5 3.8±1.0	0.481 0.082 0.307 0.849	Advanced age	0.403	Lower 0.003 0.336	Upper 0.020 0.	.010
Beta blockers Alpha blockers Baseline creatinine (mg/dL) Baseline e-GFR (mL/min)	14 (31.1%) 10 (22.2%) 1.64±0.41 42.6±9.8	19 (38.7%) 10 (20.4%) 2.22±0.99 31.9±12.4	0.484 0.830 < 0.001 < 0.001	Hemoglobin (g/dl) Albumin (g/L) Calcium (mg/dl) Phosphorus (mg/dl) intact PTH (pg/ml)	13.3±1.5 4.2±0.5 9.4±0.6 3.6±0.6 196.4±66.5	12.9±1.6 4.1±0.3 9.2±0.4 3.7±0.7 201.5±66.0	0.013 0.074 0.012 0.316 0.609	12.1±1.9 4.0±0.2 9.2±0.6 3.7±0.7 183.9±17.6	12.0±1.0 4.0±0.4 9.3±0.5 3.8±1.0 186.3±17.0	0.481 0.082 0.307 0.849 0.867	Advanced age Gender, male	0.403 -0.243	Lower 0.003 -0.336	Upper 0.020 0. 0.037 0.	.010 .114
Beta blockers Alpha blockers Baseline creatinine (mg/dL) Baseline e-GFR (mL/min) <b>CKD stages at baseline (n, %)</b>	14 (31.1%) 10 (22.2%) 1.64±0.41 42.6±9.8	19 (38.7%) 10 (20.4%) 2.22±0.99 31.9±12.4	0.484 0.830 < 0.001 < 0.001	Hemoglobin (g/dl) Albumin (g/L) Calcium (mg/dl) Phosphorus (mg/dl) intact PTH (pg/ml) Total cholesterol (mmol/L)	13.3±1.5 4.2±0.5 9.4±0.6 3.6±0.6 196.4±66.5 210.1±56.9	12.9±1.6 4.1±0.3 9.2±0.4 3.7±0.7 201.5±66.0 203.3±44.2	0.013 0.074 0.012 0.316 0.609 0.256	12.1±1.9 4.0±0.2 9.2±0.6 3.7±0.7 183.9±17.6 220.9±53.5	12.0±1.0 4.0±0.4 9.3±0.5 3.8±1.0 186.3±17.0 215.2±49.6	0.481 0.082 0.307 0.849 0.867 0.306	Advanced age Gender, male Presence of DM	0.403 -0.243 0.004	Lower 0.003 -0.336 -0.189	Upper 0.020 0. 0.037 0. 0.195 0.	.010 .114 .978
Beta blockers Alpha blockers Baseline creatinine (mg/dL) Baseline e-GFR (mL/min) <b>CKD stages at baseline (n, %)</b> Stage 3	14 (31.1%) 10 (22.2%) 1.64±0.41 42.6±9.8 37 (82.2%)	19 (38.7%) 10 (20.4%) 2.22±0.99 31.9±12.4 24 (48.9%)	0.484 0.830 <0.001 <0.001	Hemoglobin (g/dl) Albumin (g/L) Calcium (mg/dl) Phosphorus (mg/dl) intact PTH (pg/ml) Total cholesterol (mmol/L) TG (mmol/L)	13.3±1.5 4.2±0.5 9.4±0.6 3.6±0.6 196.4±66.5 210.1±56.9 167.5±91.5	12.9±1.6 4.1±0.3 9.2±0.4 3.7±0.7 201.5±66.0 203.3±44.2 179.5±102.3	0.013 0.074 0.012 0.316 0.609 0.256 0.479	12.1±1.9 4.0±0.2 9.2±0.6 3.7±0.7 183.9±17.6 220.9±53.5 190.2±97.1	12.0±1.0 4.0±0.4 9.3±0.5 3.8±1.0 186.3±17.0 215.2±49.6 188.2±100.2	0.481 0.082 0.307 0.849 0.867 0.306 0.869	Advanced age Gender, male Presence of DM RAS blockers	0.403 -0.243 0.004 -0.084	Lower 0.003 -0.336 -0.189 -0.251	Upper 0.020 0. 0.037 0. 0.195 0. 0.154 0.	.010 .114 .978 .629
Beta blockers Alpha blockers Baseline creatinine (mg/dL) Baseline e-GFR (mL/min) <b>CKD stages at baseline (n, %)</b> Stage 3 Stage 4	14 (31.1%) 10 (22.2%) 1.64±0.41 42.6±9.8 37 (82.2%) 8 (17.8%)	19 (38.7%) 10 (20.4%) 2.22±0.99 31.9±12.4 24 (48.9%) 19 (38.7%)	0.484 0.830 < 0.001 < 0.001	Hemoglobin (g/dl) Albumin (g/L) Calcium (mg/dl) Phosphorus (mg/dl) intact PTH (pg/ml) Total cholesterol (mmol/L) TG (mmol/L) LDL (mg/dl)	13.3±1.5 4.2±0.5 9.4±0.6 3.6±0.6 196.4±66.5 210.1±56.9 167.5±91.5 127.2±32.1	12.9±1.6 4.1±0.3 9.2±0.4 3.7±0.7 201.5±66.0 203.3±44.2 179.5±102.3 123.5±32.8	0.013 0.074 0.012 0.316 0.609 0.256 0.479 0.395	12.1±1.9 4.0±0.2 9.2±0.6 3.7±0.7 183.9±17.6 220.9±53.5 190.2±97.1 142.6±44.4	12.0±1.0 4.0±0.4 9.3±0.5 3.8±1.0 186.3±17.0 215.2±49.6 188.2±100.2 134.7±34.6	0.481 0.082 0.307 0.849 0.867 0.306 0.869 0.146	Advanced age Gender, male Presence of DM RAS blockers	0.403 -0.243 0.004 -0.084	Lower 0.003 -0.336 -0.189 -0.251	Upper 0.020 0. 0.037 0. 0.195 0. 0.154 0.	.010 .114 .978 .629
Beta blockers Alpha blockers Baseline creatinine (mg/dL) Baseline e-GFR (mL/min) <b>CKD stages at baseline (n, %)</b> Stage 3 Stage 4	14 (31.1%) 10 (22.2%) 1.64±0.41 42.6±9.8 37 (82.2%) 8 (17.8%) 0 (0%)	19 (38.7%) 10 (20.4%) 2.22±0.99 31.9±12.4 24 (48.9%) 19 (38.7%) 6 (12.4%)	0.484 0.830 < 0.001 < 0.001	Hemoglobin (g/dl) Albumin (g/L) Calcium (mg/dl) Phosphorus (mg/dl) intact PTH (pg/ml) Total cholesterol (mmol/L) TG (mmol/L) LDL (mg/dl) TIBC (g/L)	13.3±1.5 4.2±0.5 9.4±0.6 3.6±0.6 196.4±66.5 210.1±56.9 167.5±91.5 127.2±32.1 253.7±65.6	12.9±1.6 4.1±0.3 9.2±0.4 3.7±0.7 201.5±66.0 203.3±44.2 179.5±102.3 123.5±32.8 265.7±61.6	0.013 0.074 0.012 0.316 0.609 0.256 0.479 0.395 0.403	12.1±1.9 4.0±0.2 9.2±0.6 3.7±0.7 183.9±17.6 220.9±53.5 190.2±97.1 142.6±44.4 219.7±69.7	12.0±1.0 4.0±0.4 9.3±0.5 3.8±1.0 186.3±17.0 215.2±49.6 188.2±100.2 134.7±34.6 212.8±75.3	0.481 0.082 0.307 0.849 0.867 0.306 0.869 0.146 0.483	Advanced age Gender, male Presence of DM RAS blockers Diuretics	0.403 -0.243 0.004 -0.084 0.117	Lower 0.003 -0.336 -0.189 -0.251 -0.138	Upper   0.020 0.   0.037 0.   0.195 0.   0.154 0.   0.279 0.	.010 .114 .978 .629 .496
Beta blockers Alpha blockers Baseline creatinine (mg/dL) Baseline e-GFR (mL/min) <b>CKD stages at baseline (n, %)</b> Stage 3 Stage 4 Stage 5	14 (31.1%) 10 (22.2%) 1.64±0.41 42.6±9.8 37 (82.2%) 8 (17.8%) 0 (0%)	19 (38.7%) 10 (20.4%) 2.22±0.99 31.9±12.4 24 (48.9%) 19 (38.7%) 6 (12.4%)	0.484 0.830 <0.001 <0.001	Hemoglobin (g/dl) Albumin (g/L) Calcium (mg/dl) Phosphorus (mg/dl) intact PTH (pg/ml) Total cholesterol (mmol/L) TG (mmol/L) LDL (mg/dl) TIBC (g/L) Ferritin (ng/ml)	13.3±1.5 4.2±0.5 9.4±0.6 3.6±0.6 196.4±66.5 210.1±56.9 167.5±91.5 127.2±32.1 253.7±65.6 83.2±13.2	12.9±1.6 4.1±0.3 9.2±0.4 3.7±0.7 201.5±66.0 203.3±44.2 179.5±102.3 123.5±32.8 265.7±61.6 92.4±14.1	0.013 0.074 0.012 0.316 0.609 0.256 0.479 0.395 0.403 0.365	12.1±1.9 4.0±0.2 9.2±0.6 3.7±0.7 183.9±17.6 220.9±53.5 190.2±97.1 142.6±44.4 219.7±69.7 150.3±24.5	12.0±1.0 4.0±0.4 9.3±0.5 3.8±1.0 186.3±17.0 215.2±49.6 188.2±100.2 134.7±34.6 212.8±75.3 163.0±27.2	0.481 0.082 0.307 0.849 0.867 0.306 0.306 0.869 0.146 0.483 0.255	Advanced age Gender, male Presence of DM RAS blockers Diuretics Baseline e-GFR	0.403 -0.243 0.004 -0.084 0.117 0.232	Lower 0.003 -0.336 -0.189 -0.251 -0.138 -0.002	Upper   0.020 0.   0.037 0.   0.195 0.   0.154 0.   0.279 0.   0.015 0.	.010 .114 .978 .629 .496 .110

Figure 2. The relationship between age and eGFR changes in the fasting group



## Figure 1. eGFR changes after Ramadan according to fasting status.

There were no differences in baseline characteristics between fasting and non-fasting group regarding age, gender, body mass index (BMI), blood pressure, presence of diabetes mellitus (DM), antihypertensive medications. Compared to the fasting group, non-fasting group had significantly higher baseline serum creatinine (2.22±0.99 vs. 1.64 $\pm$ 0.41 mg/dl, respectively, p < 0.001) and lower e-GFR (31.9 $\pm$ 12.4 vs. 42.6 $\pm$ 9.8 ml/minute, respectively, p <

0.001) levels. There were no significant changes in serum urea, creatinine, e-GFR, electrolytes, albumin, lipid profile, ferritin, parathormone and spot urine PCR levels after Ramadan both in fasting and non-fasting groups. Hemoglobin (p: 0.015) and serum calcium (p: 0.012) levels were found decreased after Ramadan in fasting group. There was no significant difference between fasting and non-fasting groups in terms of the deterioration of renal functions, which was defined as  $\geq 30\%$  rise of serum creatinine (4/45, (%8.8) vs. 4/49 (%8.1), respectively, p: 0.900) and/or  $\geq 25\%$  drop of e-GFR (7 (%15.5) vs. 6 (%12.2), respectively, p: 0.642). Compared patients with stable CKD (n: 81), patients with deteriorating renal functions ( $\geq 25\%$  drop of e-GFR, n: 13) were older (64.3±11.7 vs 72.3±8.3) years, respectively, p: 0.020) and had higher proportion of diuretic usage (29 (%35.8) vs 9 (%69.2), respectively, p: 0.023). In multipl linear regression analysis, only the advanced age was found associated with  $\geq 25\%$  drop of e-GFR after Ramadan in fasting group.

Conclusions:

Fasting during Ramadan was not associated with increased risk of declining in renal functions in patients with stage 3 to 5 CKD. However, elderly patients may still be under a higher risk.

